Clinical trials
Follow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
vincristine sulfate liposome
- Development stage
- Phase 3
- Lead developer
- Acrotech Biopharma
- Modality
- Small Molecules, Lipid-based Nanoparticles → Nanoparticles → Drug Delivery Systems
- Administration
- Intravenous
01
Overview
Vincristine sulfate liposome is a sphingomyelin/cholesterol-based, nanoparticle (liposomal) formulation of the anticancer agent vincristine. It is designed to optimize delivery and prolong circulation time compared to standard vincristine, allowing for higher dosing with reduced toxicity. Vincristine acts as a **tubulin polymerization inhibitor**, disrupting microtubule formation and arresting cell division in the M phase of the cell cycle. The drug is primarily indicated for adults with Philadelphia chromosome-negative acute lymphoblastic leukemia (Ph– ALL) that has relapsed or progressed after at least two prior therapies. It has also been studied in non-Hodgkin's lymphoma and other cancers[1][3][4][5][6]. Developed by Inex Pharmaceuticals Corporation, Acrotech Biopharma, CASI Pharmaceuticals, Hana Biosciences, Talon Therapeutics, and University of Texas M. D. Anderson Cancer Center, and manufactured by Acrotech Biopharma.
- Brand names
- Marqibo
- Other names
- vincristine liposomevincristine sulfate injectionvincristine sulfate liposomes injectionvincacine
02
Targets
TUBB (Tubulin (alpha and beta subunits))
Beyond the preview
Go deeper on vincristine sulfate liposome.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Explore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Trace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Explore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Compare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Connect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on vincristine sulfate liposome.